1. Home
  2. FEMY vs VTGN Comparison

FEMY vs VTGN Comparison

Compare FEMY & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Femasys Inc.

FEMY

Femasys Inc.

SELL

Current Price

$1.22

Market Cap

11.5M

Sector

Health Care

ML Signal

SELL

Logo VistaGen Therapeutics Inc.

VTGN

VistaGen Therapeutics Inc.

SELL

Current Price

$0.17

Market Cap

9.5M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
FEMY
VTGN
Founded
2004
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.5M
9.5M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
FEMY
VTGN
Price
$1.22
$0.17
Analyst Decision
Buy
Hold
Analyst Count
2
3
Target Price
★ $14.75
$1.00
AVG Volume (30 Days)
104.8K
★ 730.6K
Earning Date
11-13-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 44.71
N/A
EPS
N/A
★ N/A
Revenue
★ $2,293,313.00
N/A
Revenue This Year
N/A
$33.96
Revenue Next Year
$294.61
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 40.77
N/A
52 Week Low
$0.29
$0.17
52 Week High
$6.29
$5.14

Technical Indicators

Market Signals
Indicator
FEMY
VTGN
Relative Strength Index (RSI) 36.99 40.45
Support Level $0.33 $0.17
Resistance Level $1.55 $0.32
Average True Range (ATR) 0.14 0.02
MACD 0.01 0.00
Stochastic Oscillator 36.46 14.91

Price Performance

Historical Comparison
FEMY
VTGN

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

Share on Social Networks: